NCT02478294View on ClinicalTrials.gov

LAA Excision With AF Ablation Versus Oral Anticoagulants for Secondary Prevention of Stroke

CompletedOBSERVATIONAL
Enrollment

474

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions
Atrial FibrillationStrokeSystemic Embolism
Interventions
PROCEDURE

Thoracoscopic LAA Excision plus AF Ablation

In this group, patients receive thoracoscopic LAA excision plus AF ablation, which means thoracoscopic left atrial appendage excision plus atrial fibrillation ablation.

DRUG

Warfarin or Novel Oral Anticoagulants

In this group, patients receive warfarin or novel oral anticoagulants

Trial Locations (1)

201129

The First Affiliated Hospital of Nanjing Medical University, Nanjing

All Listed Sponsors
lead

The First Affiliated Hospital with Nanjing Medical University

OTHER

NCT02478294 - LAA Excision With AF Ablation Versus Oral Anticoagulants for Secondary Prevention of Stroke | Biotech Hunter | Biotech Hunter